UBS AG buy 8,825,000 6.7%

eSensor LAUNCHED!!!

FDA clearance for Cystic Fibrosis DNA Test

Sales of the eSensor instrument and CF test will commence in the first half of 2006 as planned.. . James White, CEO of Osmetech said: 'Gaining FDA clearance for our first microarray based test developed for our new eSensorTM molecular diagnostics instrument is a major step forward for our Molecular Diagnostics Division and will help to establish Osmetech as a key player in the fast growing moleculardiagnostics market. In addition, this FDA clearance helps to validate our microarray technology for routine use in the laboratory. Critical Care DivisionThe Division has a strong product portfolio and is well placed to continue the growth of instrument placements throughout the world, leading to revenues from proprietary consumables for a number of years to come.Sales of OPTI instruments and consumables remained strong resulting from increased sales of the new touchscreen version of the long-established OPTI (CCA). In 2006 we will start to see an important contribution to sales from the new OPTI LION portable electrolyte analyser and the OPTI R blood gas and electrolyte analyser with reusable consumable as these products are rolled out internationally.' Molecular Diagnostics DivisionFollowing FDA approval of the eSensorTM platform Osmetech are now looking to progress discussions with strategic partners who are looking for cost effective and easy to use instrumentation and consumables to work on other complex assays both in the healthcare and non healthcare markets. The next Osmetech Molecular test targeted for FDA submission will be the CYP 450 pharmacogenomics assay, which is currently in development. James White, CEO of Osmetech commented: 'We have been delighted with the rapid integration of the CMS business acquired in July. The powerful combination of the eSensor product together with OPTI GENE provides Osmetech Molecular Diagnostics with an excellent position in this rapidly developing and growing market sector. Both products remain on schedule for launch and revenue generation in the first half of 2006'

Sales to year end up over 40%

Osmetech has reported a strong rise in sales in the latter part of 2005 with growth driven byabove-forecast revenues at its Critical Care blood gas analysis division.. Sales for the Critical Care division in calendar year 2005 exceeded $14.7m, representing an increase of over 60% compared to the calendar year 2004. Approximately half of this overall growth is due to sales to veterinary distribution partner, IDEXX Laboratories, Inc.

Vetstat Exceeds Idexx Expectations

Sales of the VetStat electrolyte and blood gas analyser have been very encouraging and continue to exceed expectations. IDEXX's sales successes and continuing marketing efforts should result in further strong growth for the foreseeable future. As the installed base of instruments becomes established, revenues from proprietary consumables are expected to increase as a proportion of this veterinary business. Following a deal with leading US vetinary hopsital chain Banfield, Idexx are contracted to supply an additional 450 Vetstat devices over the coming year.Good progress is also being made with IDEXX on the development and supply contract to create a new platform for measuring critical care parameters based on Osmetech's proprietary optical fluorescence technology and consumables. It is anticipated that this market leading product is on target for launch late 2006/2007.

Critical Care Product Range - In Production

OPTI-CCA OPTI-LION OPTI-R OPTI-2L

Critical Care Consumable Product Range - In Production

SamplerCassette Callibration DataTrol

Molecular Diagnostics Product Range - In Production

Opti-GeneeSensorBiochipConsumableOPTI Tube Product Range - Licenced to Third Party

VetStat Cassettes OPTI Tube AVOX 4000

Buisness Partners

Major Shareholders

Organisation Shareholding % Gartmore 24,109,657 18.29% Schroder 18,874,284 14.32 UBS AG 8,825,000 6.70TD Waterhouse 7,011,137 5.32 Barclays Nom 6,638,092 5.04 Pershing Keen 5,870,773 4.45HSBC Global Nom 6,544,718 4.97 Roche 2,444,688 1.8 Marlborough UK Micro Cap Director Holdings James White 208,092 Gordon Hall 104,966 D Sandilands 61,597 GB Kuenster 33,054 A Marek 26,190 ADVFN Posters 5,896,564 4.5 Total Holdings 86,648,812 65.7%

Mouse Over Images For Product Data

If regular posters would like to be included in the ADVFN figure and if you are not bothered about the figures being public then post your long-term holding here.IE the number of shares you intend to keep for say more than 6 months?Alternatively if you'd rather keep your holdings secret but still want contribute to the overall figure then drop me a line to ditchpig@ntlworld.com

when does the company quater start is it in jan or april?

There are usually 2 reporting periods.
October and July for the financial year that finished at the end of March.
The interims are published in October and we are just approaching the year end results which are expected anytime in the next 5 weeks.
Osmetech usually publish early to mid July so we should start to see some action soon.
This set of results should see that the company has reduced its 3 million annual loss to a virtual break even position. The last 2 sets of result have seen the price peak at just over 5p so given the improving position some, myself included, are expecting a 25% increase in the price over the next few weeks.

Thread updated with additional links to new products.

12355

thanks for that ditchpig, been holding for 2 years now hoping to see the price rise steadily between this july's results and january with what could be the release of a couple of products and also next year with the release of the e-nose device, only good time's ahead for this one :-))) ..

Sincerely hope that something is on the way here....since they were bouncing up n down in Jan/Feb been very quiet since...here's hoping..

here we go again this time i hope they will stay up could even reach 6p this time :-)))..

windys160.
Interesting to read your comments. I've been in this for a good number of years myself and have averaged down to just over 4p. The results are expected anytime within the next month the concenus being towards the end of the month but given yesterdays jump up I guess we could be seeing them sooner rather than later. With the notable exception of last year Osmetech tend to favour the early/middle part of the month the for results. Added to this the stories about new product launched towards the end of the month in LA I expect we should easily pass 6p this time. Best to hang in on tight. Could be a rough ride over the coming week. I notice a number of old derampers have reappeared on the AD VFN board which is usually a sign of action on the way. Thankfully we seem to be free of that sort of behavouir here.

Regards,
DP

let's hope they stay over on advfn as all i can see with share is blue sky would like to see it recover to the 13p > level of a few years ago now that would put paid to any derampers, i feel that this company as a long way to go yet, will be holding for a long time to come :-)) cheers windys

Same here windy though given the activity of the last few days 13p does not seem quite so far away now.

There is story in Guardian of rumours of more deals on the way.
http://www.guardian.co.uk/.

Osmetech was marked 0.2p higher at 4.25p on the back of speculation that the diagnostics company could announce two deals at its upcoming annual shareholders meeting.

Looks like their could be some truth to this deal specualtion.
The MM seem to be fighting amongst themselves to grab the shares this morning.
I've not seen it this active since January.

L2 Brief.
On the Offer.
TEAM 4.35
KBC 4.35
SCAP 4.25
WINS 4.25
MLSB 4.2
EVO 4.1
KLWT 3.75

On the bid
EVO 4.6
WINS 4.65
MLSB 4.7
KLWT 4.75
SCAP 4.75
KBC 4.75
TEAM 4.85

13179

Personally I shall wait to see some substance other than the bollocks from rampers.

what has been said on this thread that is bollocks to you, can't you see the potential of this share over the next two years, looks pretty rosy to me, but then i might be one of the rampers that is talking bollocks, but if we're right in what we think then we'll be the one's sat on a tidy profit not you :-))...

He's best ignored I think. He has posted similar message round all the other boards as well.
Good to see that the price has held its gains today. A few days to stabilise the price at this level before the push north resumes would send out a positive signal. We've had some steady buying today which will further strength our position.

13381

Added a table of the major shareholders.
Anyone know who ELEONORA INTERNATIONAL INV LTD is?
They seem to have sneaked in under the radar.

13484

Osmetech will announce two new contracts I have heard from a reliable source r worth a seven figure sum. Does anybody know anything about the links os has with a Irish biotech.

let's hope your right, theses sort of contracts can only help push the price higher, let's hope they stay up this time rather than doing the norm and falling back a few weeks after the results come out. :-))

The two contracts mentioned in the Guardian so hopefull news soon, hoping for a spike the share price soon..fingers crossed

do you think we could reach the 6p mark this time, what with new contracts and hopfully a good set of results ?

this is a thread.....

AntiADVFN for SURE

what's happening the share price, why is it falling so much when the results are due soon, are the results going to be bad? what about the contracts are they still going to be announced

I agree with your comments.Osmotech are due to release 5 new products during 2004(I.C. 6 feb)- ihave not seen any announcements of these taking place and its now July?

maybe they will go mad after the results and release them all at the same time, if so the price could sky rocket as they have some excellent product in the offing let's hope they release something this year, been holding for a long time now and still waiting for the release of their e-nose product, now with other products in the pipe line as well i feel that this company as a long way to go yet and in time we could see a healthy profit from this company, does anyone feel the same or am i the only one that see the huge potential of this company in the long term or is it that poeple are just sitting back waiting for the release of one of their products and then they will all jump in ? cheers windy

I think they have potential but the lack of news is always prone to make you a little twitchy? patience is such a difficult attribute to acquire!Know where I can buy some?

Relax. It's the standard Osmetech routine. Price falls for no real reason on no news and then out of the blue, blam a major news update and the price gains 25-50% in a few days.
Osmo have always been poor at news management and you have to look for clues about news where you can.
The article in the Guardian is a good start.
http://www.guardian.co.uk/business/story/0,3604,1251115,00.html

And this link to the exhibition where Osmetech will be LAUNCHING NEW PRODUCTS
http://aacc.org/2004am/exhibitors/NewDisplayDetail.asp?Category=Blood+Collection&CompanyID=92

I think most of you are jumping the gun. Most of the good news is not due to the later part of this year so chill out and enjoy the ride. We are only seeing the retracement of the blip caused by the story in Guardian. No doubt T10's who bought in on the strength of the Guardian story taking a loss again.

will this be the week were the long wait is over for the arrival of new products and the share rises to new year highs? lets hope so :-))

do have any orders for thier new products which are being launched this week?

any news on product release yet, price seems to have regained slightly hopefully they have got lots of orders for these products also

WHAT WILL TODAY BRING ?

More of Windy me-thinks. :-)
regards

A more indepth update about todays announcement.

http://www.lemminginvestor.com/OsmetechMadanoPRupdate300704.html

at last some positive news let's those order books fill up now and roll on the 6 august when the results come out :-))

Windy

I bought into this company at the beginning of this year and don't regret a single penny. They are definately going places, although I wouldn't be surprised if the prelims on the Friday do not set the markets on fire. They benefitted to the tune of one million from the SARs virus and are expecting much greater costs from developing the OPTI and imtergrated VIP ranges. It will be interesting to see what sales they have achieved with the current range of diagnostic equipment, if sales are up, all development costs will have been self financing and the results will look really good. However if sales have not accelerated, the converse may be true. Whatever, in the long term I am staying in and lets not forget that the market for the VIP is estimated to be in the region of $1.4 billion, (US alone!). I may even top up.

Good luck

Regards

PTH

ptholden i agree it is a good time to top up now as i can only see this share going one way in the near future and that is up :-)), also what will the VIP be worth worldwide? with such a strong product this company is well on the way to earning some big money in the future, could we see 6p by friday let's hope so :-))) cheers windy

Must say all I have read gives cause for your optimism.

I will be watching what occurs as I have a small interest in the company, so you can call me biased.

I think the possibility of 6p or more is real, so fingers crossed.

windys160,
6p by Friday would cause too much volatility. We should be looking for steady and sustained growth from now on. The quick spikes caused by short term traders have not done long term holders any favours over the last 12 months. I'm sure we would now be sitting at a higher price had it not been for the volatility caused by idiots like Steven Foley in the Indy telling people to go short. The MM seem to have managed this very carefully this time, they opened the spread up to effectively kill the day traders just when it looked like it was going to be lift off last Friday.
Well no fireworks at the end so guess we will have to wait and see what tomorrow brings.

dicthpig always thought this was going to be med - long term thing, i have to agree with you on people being advised that this was a short term share not on your nelly, would have thought people would have guested that by now, let's hope today when the results come out we get the news we've been waiting for about sale's of the new products and the price starts on the upward trend that we have been waiting for so long now. let the good times roll. cheers windy

there we have it news of a nice little contract for the at least 10 years pre tax losses reduced and a serious increase in sales all looking good to me, now lets see it reflected in the price :-))

up 10% before trading.............this will hit 5p today :-))))))

plenty of buying today but keeps droping back slightly on the sell are the MM playing with us today?

Unless you are in short term, it doesn't realy matter what the MMs are up to. This is all very good news for the long haul. IMHO

Of course.

Monkey shake the tree, all the coconouts fall out.

Hold tight!

Big Al says:-

OMH - agreement opens verterinarian market to technology. "The impact upon the next financial year should be significant".
Might fly!!
http://moneyam.uk-wire.com/cgi-bin/articles/200408060700086991B.html
Results - http://moneyam.uk-wire.com/cgi-bin/articles/200408060700086992B.html

Ha......who's gonna blink first. Time to enter m'thinks.
regards

Massive buys already 5M and rising.

Not at all surprised here with the news and results.

could we reach 10m buys today :-))

The vet tie-up came as a bit of a surprise, another market to tap in to and quite a big one by the looks of it, 10 million looks easy today, I wonder how long the price will be kept down? As long as it stays this low, it surely must be regarded as a buying opportunity?

Good luck to all

Regards

PTH

still keeping the price down, surprised by this after .45p gain just before the start of trading, buying seems to have slowed down as day goes on, results and positive news all good but price is not reflecting this as yet hope to see it rise soon :-))

What time frame are we looking at on this one +12 months or longer.

Christ. What does this company have to do to get a positive reaction from the share price? Some truely fantastic news buys 3 million more than the number of sells and we end up down. EVO have killed any rise today by sitting on the offer all day. I wonder what their game is.
I'll update the header with the new info over the weekend.

still going down shocked to see such a down turn in the price was expecting it to rise this week anyone with views to why the price is still going down, with the company giving us the best news we have had for a long time and getting closer to making a profit next year this is only good for the price surely :-((

Morning All, Does Anyone Know the date of the final results yet, (due Q3 2004 )

some people amaze me.....LoL

why are they keeping the price down what are they affraid of, this comapny is doing well with plenty in the pipe line but still they fall ;-( is there any ryhme or reason for this surley they should be 6p by now...

Hmmm....Maybe the MM's are too surley. Miserable bastardo's :-)
regards

So whats happening to the share price. Maybe the city just dont like them?cant sit on this much longer. Good news and a declining share price do not send the right messages

More good news from OMH.

Osmetech PLC
01 September 2004


1 September 2004




NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO
THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION



Recommended Offer by Evolution Beeson Gregory on behalf of Osmetech plc to
acquire the whole of the issued and to be issued share capital of Molecular
Sensing plc


Summary




Recommended share for share offer, that will be made by Evolution
Beeson Gregory on behalf of Osmetech, for the entire issued and to be issued
share capital of Molecular Sensing on the basis of 47 new Osmetech Shares for
every two Molecular Sensing Shares.



Offer values the existing ordinary share capital of Molecular Sensing
at approximately 3.1 million and each Molecular Sensing Share at approximately
86.4 pence, on the basis of the Closing Price of 3.675p per Osmetech Share on 31
August 2004 (the last dealing day prior to the publication of this
announcement).



Offer price represents a premium of approximately 92 per cent. to the
Molecular Sensing Closing Price of 45 pence per Molecular Sensing Share at the
close of business on 31 August 2004 (the last dealing day prior to the
publication of this announcement).



The Independent Molecular Sensing Directors, who have been so advised by
Insinger de Beaufort, consider that the terms of the Offer are fair and
reasonable and the Independent Molecular Sensing Directors will recommend all
Molecular Sensing Shareholders to accept the Offer. In providing advice to the
Independent Molecular Sensing Directors, Insinger de Beaufort has taken into
account the commercial assessments of the Independent Molecular Sensing
Directors.



Commenting on the Offer, James White, Chief Executive of Osmetech said:



'We have evaluated a variety of alternatives to achieve our strategic aim of
expanding the non-OPTI revenue base, utilising our existing distribution network
more effectively and enhancing the attractiveness of our vaginal infection
product ('VIP').



The genedrive product achieves all of these criteria and gives us a strong entry
point into the fastest growing market segment of DNA based diagnostics.


We believe that the genedrive platform, when combined with LGC Limited's
HyBeacon technology, should not only enable us to penetrate successfully the VIP
market, but should also allow us to provide other tests for important conditions
in the near patient setting.



The genedrive platform is itself at an advanced stage of development and
substantially all of the research and development expenditure has now been made.
Molecular Sensing, however, is dependent upon partnership and licensing
agreements to bring products to market.



The recent agreement that Osmetech has entered into with IDEXX has demonstrated
our ability to secure partnerships with companies outside the medical industry
and we believe that there are opportunities to market the product for sale in
sectors other than healthcare diagnostics, including forensic and research.



The highly reliable revenue streams from OPTI provide a solid base from which
the business can develop its exciting opportunities for further growth. We will
shortly have three strong technology platforms to meet the needs of the
international diagnostics market - blood-gas analysis, e-nose sensing and
molecular analysis. Osmetech has been transformed from a technology company with
potential into a rapidly developing international diagnostics company operating
in high-growth market sectors.'



This summary should be read in conjunction with the full text of the following
announcement.



Enquiries:


Osmetech Molecular Sensing

James White (Chief Executive Officer) Alison Kibble (Chief Executive Officer)

David Sandilands (Chief Financial Officer)

Tel: 020 7849 6027 Tel: 01225 706 245


Evolution Beeson Gregory Insinger de Beaufort

Rob Collins Stephen Goschalk

Stuart Andrews

Tel: 020 7071 4300 Tel: 020 7377 6161


The Madano Partnership

Matthew Moth

Tel: 08702 40 62 43

LONDON (AFX) - Osmetech PLC said today's all-share offer for Molecular
Sensing PLC is a "dream deal" that will enhance earnings at least as much as its
last deal with IDEXX Laboratories Inc, signed last month.

Though chief executive James White declined to put a figure on how today's
acquisition might boost earnings, he said it will at least be equivalent to the
"significant uplift" in revenues forecast at the time of the IDEXX deal.

Revenues will really start churning through in 2006-2007, following the 2005
launch of Molecular's lead product, White added.

This late-stage product, called the genedrive platform, is a combination of
an instrument platform and chemistry and is used to detect infectious diseases,
mainly vaginal infections.

It would compliment Osmetech's Bacterial Vaginosis test, which can diagnose
sexually transmitted diseases within half an hour and is scheduled for a US
launch in H2 2005.

The BV test, based on the group's electronic nose technology, is being
combined with other tests for diagnosing and differentiating between five of the
most prevalent vaginal infections, including chlamydia and gonorrhoea.

White added that the genedrive platform could also be used in genetic
testing, to test patients for thrombosis, or in the vetinary or forensics
market.

"(The deal) enables us to take a late stage product, put it through our
distribution and manufacturing facility, and get into the fastest growing area
in diagnostics, the molecular diagnostics sector," White told AFX News in a
telephone interview.

Following the acquisition, the company has three main revenue streams: the
gas-analysing OPTI business, the IDEXX deal -- a 10-year agreement to provide
OPTI analysers to the world's largest animal health diagnostics company -- and
this latest, for the vaginal infection or genetic testing.

The Molecular Sensing acquisition strengthens the group's product offering
in the vaginal infection area, and gives it an entree into the genetic testing
market.

"We've got three or four horses out there, they're all going to have a
positive impact, it is a timing issue now," White told AFX.

The market for molecular diagnostics is growing at over 20 pct a year and
the overall diagnostics market is currently worth 22 bln usd.

does any one have any idea why we are having suck GOOD news yet the share price has dropped around 10% in 3 weeks.

it seems that people have not cotton on to the potenial of this company as the price is still falling, with so many new products on there way and with the molecular sensing deal all should be rosy for this one, i will be topping up at this level as potenial med term is excellent, anyone else agree that there should only be blue sky from here on in. cheers windy

Have this one in my Med-Long term folder Windy and can't say I am at all bothered about the current SP. Give it time and reap the rewards.

Regards

PTH

ptholden i agree with you, it's shame that more people don't see it that way, as there is still plenty of selling going on

Windys.............I agree with you...........my research tells me this can be big........forget the main product this company has planned well......longer term this could be a good one........I'm in.....staying in and will top-up.

can any one tell for the reason in todays price change as i cant seem to find any relevent news?

Babykitcat - OMH's offer for MOLS received 86.5% acceptances yesterday (see RNS) so it's in the bag. Offer extended to mop up shares to get to 90%.

i noticed on 08/10/04 that Barnard Nominees Limited has an INTEREST in osmetech 6.93% all looks to be getting better......I HOPE!!!! an increase of just over 1% form what the company results say

Interesting post from Bucketfull on advfn (is 2005 going to OMH's year?):

Extract from Mike Walters' comments as of April:

"Put a price of 25m on OPTI, and go back to the October 2002 share funding which effectively valued VIP 5 at 10m, and you have a low case 35m for the company or maybe 6p a share.

You could argue a take-out of 75m for OPTI. If you allow for the poor investment climate when VIP 5 was valued at 10m and add something for subsequent progress, you could project an uplift to 15m. That yields a notional 90m or 15p a share."

NB: The article precedes both the MOLS aquisition and the two IDEXX deals.

where could you see the share price going, taking the other deals into consideration could we see 25p or 30p in the coming years? or do you think they will do a consolidation and get to that price by doing a 10 to 1 ?

Can anyone please tell me, I have noticed over the last few days the vast majority of trades of Osmetech have been sells.
With all the recent purchase of MOLS and improved trading seen by the latest results, why does all the confidence been lost in OMH, hence the weak price.
I hope someone can help me understand this stock.

Regards

Smarty Marty Boy

Marty Boy
The trades for the past few days, Buy's outway sells 2-1 MM bid 3 Offer 3.1 thats what people have been trading. MM trying to make the buys look like sells to keep price down.

Thanks Leedslad for that.

I have been looking on the trades on moneyam and most of the trades seem to to be red (unless I am colour blind).

If you are right, how can the MM's make the buys like sells.

I still refer to the purchase of Mols and the latest results. I still don't understand why there isn't any sustained movement upwards.

Please comment on the above.

Thanks & regards

Marty Boy.


PS This might seem like a silly question, are you from Leeds?

Marty

Buys and sells are reported simply as trades and it is up to AM's algorithm to decide if they are buys or sells, by calculating where they fall in the spread. If they fall in the middle, they go down as 'unknown.' Because the actual spread is often quite different to the reported spread, it is easy to understand how they often go in the wrong column. For example, a stock with a reported spread of 0.055-0.075, sees a trade go through at 0.063, this will go down as a sell, but the real spread may be 0.058-0.063, in which case it is clearly a buy. Delayed reporting will also blur the process, as the spread will have probably changed by the time the trade is reported. MMs may also manipulate the data, just to make it really difficult!

Hope this helps.

Regards

PTH

over 12000000 shares traded today does any one know of a reason for this?

ok better make that 23000000 thats another 1000000 million in 30 mins!!!!!!!!!!

The RNS's look good today guys - I think this is the turning point for OMH...

on wards and UP wards its about time for this one

And yet another RNS - US approval for e-nose.....

seems we could be on to a winner (when) the pennies roll in!!!!

LOOKS LIKE SOMEONE WAS BUSY AT 3.45PM SPLASHING OUT

See what you mean - they also bought knocking for another half million at 4pm !

Definitely looks as though the Molecular Sensing overhang has gone and buyers are coming back in on the back of the progress shown in the RNS's.

all looking good just i have not really seen much price change % in the past year taking into account all the GOOD news we have had what do you think?
i still reckon i might have a top up though as i really do feel that in 2006/07 these are going to be big any thoughts

Good to see last minute buying today. Looks like January could be a repeat of last year. I'll update this thread over the next couple of days with all the latest info.

(DITCHPIH) i will be keeping my open

So looking very good for a decent run up to the results. Price has finished the year the highest it has been for 3 1/2 months and is going to open on the 4th higher than a year a go.
Should definately see 5p in the run up to results.
Next big event. The crytalisation of one of the Idexx deals with the launch of Vetstat in January!

DITCHPIG do you know when in jan this is launched i have been a share holder for 3 years and have had a really rough ride its about time i saw some returns from the 15p years two years ago.
what are your thoughts on this stock and how well do you feel this will advance as i feel the potential of this stock im HUGE

Vetstat which is an Idexx badged version of Opti for the vast vetinary market is to be launched on the 8th January.
JW has said that within a couple of years this product could double the number of opti devices in use. Remember the majority of revune long term comes from the sale of consumables for these products.

I am in the process of updating the header. Please bear with me.

looks like we could break 4p by mid jan then going well today im please to say

19478.

Positive start to the day.

DITCH were did u get all this ref from as i just been on OMH web and found no new news THANKS

I emailed Idexx pretending to work for a vets and they gave me a load of info!


The JW quote is from the results.

good thinking i like it will have to see what the share price does over feb-apr

Thread updated with UTI Link.
19853

Wot no nobclare?

Good init!!!

I think she's DONe a runner

somebody call?

obclare - 06 Jan '05 - 17:48 - 100 of 100 (squelched)

DITCHPIG,

I have re aligned your original post to the left as it was pulling the following posts across to the center as well.

Ian

Ian,
Fair enough. The code was all a bit rough and ready and cobbeled together on the fly, by hand.
Still I quite liked it in the middle!

The 10 Year agreement with Idexx alone secures the future of the company. If EVO's prediction is correct and the Idexx Opti deal does generate equivalent reveues to OMH Opti then Osmetech becomes profitable and comfortably so. What value do you place on a company with revenues in excess of $15 million making a profit in the region of $5million?

Then there is the other deal with Idexx. We do know they are developing a new product for Idexx but what form this is going to take is anybodies guess. Could it be a development of the mysterious hand held OPTI IV, a device Roche has already agreed to sell and market?
What of the genedrive? Will we see Idexx licensed developments of this technology? I suspect so.

What of the announced but yet to appear electrolyte only product for vetinary application? Idexx already sell the AVL9180 as Vetlyte and this company http://www.somagen.com/html/chemistry/chem_electrolytes.htm are still advertising the AVL9180 as an Osmetech product. As the AVL9180 does not currently sit comfortably within the current Roche blood gas range it having more in common with OPTI than Omni, are we going to see an announcement that Osmetech have aquired this product range from Roche as well??

2005 is going to be one hell of year for Osmetech holders.

i might have a topup then cant wait for divi payements which should see something end 2006 what do u reckon im with u on this reckon this company is going to be the next microsoft!!!!

'divi', 'micro' & 'soft' all in the same sentence. Sounds like your refering to DONclare. LOL!

-------------------------------

Good luck with the top-up, I dont think we will see much lower than todays price, if at all. With the absolute low at 3p support risk / reward looks fantastic for a long term hold.

Bangers

Some of the larget trades from the last 7 days

05/01/05 14:41 3.65 600,000 O 3.5 3.7 Buy 999,611 1,102,420 0
05/01/05 10:37 3.5 555,280 O 3.6 3.8 Sell 350,051 725,210 0
07/01/05 12:23 3.75 515,078 O 3.5 3.7 Buy 1,221,263 1,135,000 600,000
07/01/05 09:22 3.55 500,000 O 3.5 3.7 Sell 200,000 500,000 100,000
04/01/05 10:23 3.6675 500,000 O 3.45 3.7 Buy 699,150 114,702 0
04/01/05 12:12 3.75 500,000 O 3.55 3.75 Buy 2,232,055 498,549 0
04/01/05 16:31 3.7 500,000 T 3.6 3.8 ? 3,574,039 1,774,952 500,000
06/01/05 14:56 3.67 300,000 O 3.5 3.7 Buy 435,581 169,157 0
06/01/05 14:56 3.7 300,000 O 3.5 3.7 Buy 735,581 169,157 0
07/01/05 09:44 3.55 300,000 O 3.5 3.7 Sell 275,000 800,000 100,000
05/01/05 10:42 3.6 300,000 O 3.6 3.8 Sell 370,051 1,025,210 0
07/01/05 11:02 3.7 300,000 O 3.5 3.7 Buy 706,185 800,000 100,000
04/01/05 12:49 3.6 300,000 O 3.6 3.9 Sell 2,695,708 1,181,049 0
31/12/04 11:29 3.5 300,000 O 3.35 3.5 Buy 305,053 67,690 263,037

did they release there new product on the 8th as suggested as there is no news of it yet ?

Windy

VetStat is due to be launched at the North American Veterinary Conference which runs from 8-12 Jan. So there's plenty of time yet. However there is a chance the company will not notify the market as they (OMH) are not doing the launch. The PR department seems to have improved recently so fingers crossed that we get an RNS.

with other products due for launch as well this year we could be looking at a very good year indeed :-))

Well no RNS. Can't say I'm that shocked. Until we applied investor pressure we weren't going to get an RNS about the Sysmex deal and we weren't going to get an RNS about Elenora either. I say give it a couple of days until the NAVC show has finished then can someone else email Osmetech and ask them why we have had no RNS about Vetstat when we already know about it because Idexx have been quite happy to tell anybody that asked.

I guess EVO and their cronies want a bigger slice of the cake than we think.

thats the thing with this share the price/change/news never really co inside with the share movements its as though they dont want this baby to take off and then move in for a cheap buyout when all the hard work has been done. something not quite right as we are a company 10x stronger than 2 years ago with more $ in the bank and when i spoke 2 JW he even told me there would be no more tapping up share holders in the near future (mind u i suppose he would say that).
one thing would b nice is rather than telling us about all these new products being launched why not let us know the kind of people buying/renting them and maybe to inform us on future plans on driving sales as all i ever read is what they are launching.
point is im sure we all would like to see the back of the 5p mark!!!! and maybe see 6-7p may-june

Mondays sells and the drop in price I think are over done.
I suspect the price rose last week partly because of short termers jumping in expecting an RNS about the Idexx launch who bailed when we didn't get one today and those selling who have fallen for the bollocks badly researched article in Chronic Investor.
We may see a rebound during this week coming week.
20467

Looks familiar?
http://www.scilvet.com/International/3-Products/Products%20PDF%20D%20E%20F/Products%20PDF%20E/Opti-CCA-eng.pdf

Looks like someone else is already selling OPTI in a vetinary environment.
21056

lets hope theres more out there as well all looking in our favour IMO thanks DITCPIG roll in end jan may be they have some more news for us

RNS Number:3203H
Osmetech PLC
13 January 2005


Osmetech plc

Notification of Interim Results announcement


Osmetech, the international diagnostics group, is to announce its interim
results for the six months to 31st October 2004 on Thursday 27th January 2005.

DP will be interesting to see how the sales have gone up by

Shares Mag Comment 13/01/05

A stock i hold. Prospect for positive surprise is considerable as the medical diagnostics group has struck several exciting deals that should ultimately enable it to break even much sooner than originally envisaged. Gervais Williams, Gartmore UK & Irish Small Co Fund Manager.

Having nothing better to do with my boring night I thought I'd go on a little rampathon.
I've kicked off a discussion thread on this USA board in the hope of alerting our American chums to the potential of Osmetech.

http://www.stockselector.com/forum.asp
http://www.stockselector.com/board.asp?symbol=OSMEF
http://boards.stockselector.com/board.asp?symbol=SSBoard2
http://boards.stockselector.com/board.asp?symbol=SSBoard8

lets hope it works well done

Looking good today. Some big buys going through and the highest volume we have seen in a while.

Still getting all these trades at 3.5 going through. They look like sells but given the quantity traded if they were sells the price should be down not up.

micram 1 mill buy 5 mill sold today anyone know?

spoke to david sandilands from osmtech invester relation last week interim due in two weeks sounds like it will contain some positive new re vetstat product, he said they have not released any new about the product as it was idexx promoting the product so any news about the deal will not come out until osmetechs interim comes out but was very keen to say that the news flow from osmetech about deals and products will come as i siad to him that the news flow from them is few and very far between his reaction was to say that so companys will release news to say it is wednesday as it were has with osmetech they would only release new when they felt the timing was right was the company and sharholders alike whatever that is supposed to mean ;o when i asked about a possible conslidation of shares again he said it would be possiblity in the future but only be to done the benifit of the company and to the shareholders so let's wait and see, with plenty of products on offer from this company the prospect bold well and let's hope that they don't consoliadate for a few years to come.

sorry about grammer still half asleep

micram,
Don't take the trade quantities at face value. Over the last few month there have have numerous large trades made at 3.5 quite often T trades. There is a suscpicion that it could be Elenora adding to their pile again.
If the volume of shares traded at 3.5 yesterday had been all sells then most certainly the price would be far lower than it is now.

windys,
thanks for that.

next week should be a very interesting week i might even have a 7 day trade on this on for a few bucks or culd just have ANOTHER top up wwill be nice to see what the profits are any one any thoughts?

interesting keep getting this from natwest stockbrokers on line when trying to but OMH shares.
Unfortunately a firm quote is not currently available for your order.

sure the NMS is 50000 i just below this strange never had this before on OMH been trying for nearly 20 mins

ok cop aload of this you can SELL all you want no problem but u cant buy theses shares at all i just checked!!!

ummm that looks good then..........

Update with wild rumour...

oblivously not going to happen but last time i seen this the company announced a take over next day.
wonder if there is something in pipeline for tommo (news on research)really strange as i was trying for ages so it was not just my computer i will try first thing tommo and let u know.
For chartist out there i notice the RSI is at 70

babykitkat,
others are reporting that the quantity available to buy became very limited, however you could sell at 7*nms.

Bangers, are you reading? Can you give Mr Kitkat a chartist view?

DP what a year we COULD be install 4!!! thanks

still cant get a firm price!!! DP any ideas

Kitcat.
Charting these smaller stocks is best kept simple. Oscillators like RSI, Stochastics etc are generaly used in conjuntion with each other to find short term entry / exit points but only work well on more actively traded stocks. Small stocks like OMH can go on being 'overbought' (RSI 70) or 'oversold' RSI 30 for days or weeks therefore giving false signals. Far better to keep it simple and use price, volume, moving averages and MACD.
Hope that helps and its just my opinion.
All the best

so what happens when the pink 200 thingy line turns north Bangers?

thats it i managed to get a firm quote

L2 for them that wants it.

Bid

2 200,000 3.60 3.75 200,000 2


Time Name NMS Price Price NMS Name Time
Bid
10:29 EVO 100,000 3.60
10:40 WINS 100,000 3.60
07:51 TEAM 100,000 3.50 -
07:53 KBC 100,000 3.40 -
07:35 MLSB 100,000 3.25 -
07:50 KLWT 100,000 3.25 -
07:52 SCAP 100,000 3.25 -

Offer
- 3.75 100,000 MLSB 07:35
- 3.75 100,000 SCAP 07:52
- 3.80 100,000 KBC 07:53
3.90 100,000 EVO 10:29
- 4.00 100,000 KLWT 07:50
- 4.00 100,000 TEAM 07:51
4.00 100,000 WINS 10:40

not 100% on this L2 but thinks this looks good?

yip!!!

Looking very strong now, rising on heavy volume. Seems both MM's EVO & WINS are trying to fill orders, pushing the price up in their competition.

keep it up

10:29am 900,000 sale (OR WAS IT!!!!)

a 900k sale wouldn't put the price up!

precisley not right all this market making is it really!!!! all i say is just wait till share starts to go on a roll and we not be making post's like this

DP been looking @ various web sites and i notice you have made your own for this company looks nice you seem to be very much into this company good on you i been waiting 5 years for this the grow

Well someone has got to make a stand BK. Osmetech seem determined not to publicies themselves so if I make a bit of an effort and it gets a few more people on board all the better. After all we all benefit and hopefully it bugger up evil EVos plans.

L2 is looking strong this morning.
Only SCAP on the offer at 3.75. Next stop scap at 3.8 then we have 5 MM on 4p or more. That's 1 more than friday.
On the bid side Evo and MLSB lead the pack on 3.7 with Wins next on 3.65.
A decent bit of buying could see us push through 4p today.

great but knowing this one it will go DOWN!!!!
you do much trading on this (7 days) or do u hold

Windys160,
Thanks for your input. Interesting what DW had to say. Atleast it confirms we will see something about Idexx in the results. Which can only be good. I wonder how much of an upfront payment Osmo got from Idexx for developing it?

BK . Only ever take a trading position to provide a bit of pocket money leading up to the results. Took 250ks worth a couple of weeks a go. The rest of my holding stays put currently got 1.8 million built up over 3 years for the long term. This baby is going to allow me to retire early.
Hopefully.

MY THOUGHTS ENTIRLEY nice tight spread looking good

Spread pretty tight, no movement on L2 yet. L2 has its uses for non sets stocks just a shame it does not tell you how many the MM have got left to sell before they move up.
Scap are holing us back at 3.75. Depends how impatient EVO get. We may see a micro move up so EVO can go top of the back again.

just had a little top up

Nice one Kitkat, i recon you timing could be pretty good. All we need is a few fair sized buys and this IMO will move fast!

KBC have now joined EVO and MLSB on the bid at 3.7 This will place more pressure on Evo to move up. Now 6mm sat at 4p and above.
Only scap spoiling the fun at 3.75 but given the buys so far today they can not stay there all day. When they've gone we'll see a big jump to 4p on the offer

thank please keep me posted

and they DO look like sells aswell not mm playing bat & ball

I think most of us have been stiched up by EVO and the MM's games over the last couple of years, the real enemy is not each other it is EVO and the MM's. They are the fools we need to be making money off rather than giving it to them. This share needs people with balls of steel, you have to ride out the rough with the smooth, the ups and down and the pumps and dumps.
Study the company, look long and hard at what they are doing and how they are doing it. Look at the way Osmetech has transformed itself in the last 18 months. Look at the fundementals, look at the potential market for their products look at what the management have done to safe guard the long term future of the company.
Buying OPTI and MOLS were a strokes of genius and the company is still looking for similar deals. Despite all the knockers both on here and III Jimmy boy and co have done a great job stream lining the company and getting it focussed.
VIP5 and GENEDRIVE are going to be the real cash cows are a within 12 months of being launched. Osmetech will then have dipped two toes into a two multi billion dollar markets. By listening to the derampers and the notsoHOT pump and dump merchants now you could be kicking yourself in 18 months time.

Buy your shares and hold the bloody things. Don't sell them back to EVO at the first sign of a tree shake. EVO are well aware of what the future holds, why would they have backed Osmo financially if they did not? EVO will be hanging in to the glory days and so should you.
Become a TRUE INVESTOR Buy your thousand quids worth of shares and hold on to them through thick and thin.
18 Months from now I am sure you will be more than amply rewarded.
Have you got balls of steel or testicals of tissue?

good point im in long term 2 yrs and i want results

ANYONE want to hedge a guess as to what the price will FALL/RISE (% will be easier) to tommorow winner gets to smile at the rise or think WAN**ERS if if falls!!!!.
may be we could try and get yoy in the ring with a M/MAKER ding ding!!!!
LOL

Its just a guess but i think we will get a markup between 5-10% first thing that will be sold into, we will then drift into the red but will close up 3% on the day.
Whats your guess?

UP 10% IN THE FIRST HOUR THEN FALL BACK TO BELOW THE OPEN PRICE COMING BACK TO LIKE U SAY ABOUT 3% UP ON THE DAY.
MIND YOU DONT QUOTE ME BUT PRETTY SURE WHEN RESULTS CAME OUT 2003 WE HAD A 20% INITIAL RISE BUT THINK THEY WERE YEAR END LIKE I SAY DONT QUOTE ME .
KNOWING THIS SHARE WILL BE DOWN 15% ON THE OPEN LUNCH TIME COMING BACK TO UP 4% AND AT THE END OF TRADING ENDING DOWN 6% !!!!! LOL
SHOULD BE INTERESTING WHAT EVER IM NOT REALLY BOTHERED WHAT THE PRICE DOES JUST WANT SOME GOOD NEWS.
REALLY SUPPRISED THE ISNT MORE ACTION GOING ON TODAY

In other words your like me and not really sure...LOL!

Anyway EVO have just improved their quote
Level 2
1 v 1

just noticed that and price gone up a TAD

TEAM just moved theres up 2

13:55 EVO moved up AGAIN!!

nice to see the shares have gone down maybe reach 3p looking good

nice 1 jusy hit 3p now lets look for 2p looking like might hit 2.5 though looks good

LOL
Looking at the trades and the spread the MM have played a blinder today. Looks like a load of shorters could get stung. EVO now back on the bid and only wins holding the price at 3.3.

when u think about it there was NO CHANCE never in a month of sunday the price could go up look at all the dosh they spent over past year on aquasitions

Todays drop was over done. Traders easily panicked in to a sell helped along by shorters looking to make a quick buck. Still looks like they have come un stuck.

So you live in Nottingham then babykitkat....

yeh nottm why u local 2?

cinderhill area

BLINK NORA

DRIVE THROUGH THERE NEARLY EVERY OTHER DAY

small world.

U LOOKED ON III SITE EVERYONE IN PANIC MODE!!!!

Sorry for off topic everyone

Ditchpig/Babykitcat
West Bridgford myself.

GREAT TO KNOW THERES OTHER PEOPLE IN NOTTINGHAM WITH SENCE ( ASSUME DITCHP & FLAT CAN STILL SEE POTENTIAL) UN LIKE ANOTHER SITE WHAT ARE BOTH YOUR THOUGHTS

PEOPLE ARE PULLING OUT WITH A VIEW OF GETTING BACK IN END OF THE YEAR (COULD BE TO LATE) COULD....AND THATS A BIG COULD!!!!

Very comfortable with this one. Medium & long term look rosy.

Evo took a 1million sell on the nose and then upped the bid. I think that tells you all you need to know. A new broker note from EVO is expected v.soon. It will be intersting what it says. If they up their rating from add to buy we could start to see some serious action. Todays blip was expected. You don't put together the kind of deals the company has in the last 12 months without it having an effect on your costs. They have also taken on two very senior staff.

Geoffrey A. McKinley, Ph.D, is joining as Vice-President R&D and Business
Development with Dick Keys, Ph.D., appointed Senior Director Chemistry and Assay
Development.
Not forgetting the company already have Alfred Marek on board head honcho at AVL and a senior figure in Roche.

Are people of this calibre really going to join a company that was showing all the signs of going phut in 12 months?

Price has retraced to pre results mini rally level so we are no worse off than we were a few months ago. Actually we are better off because this set of resuts were expected to be the bogeyman. Come July we should see an increase in turnover, and, if the Idexx deal is going well and R&D has not been so excessive that is there tantilising possibility of a sniff of a profit.

Long and medium term, it's a no brainer.

WANT TO POST THAT ON III SITE THINK THEY ARE HANGING THE NOOSE!!!!

TIPPED BY CITYWIRE 10.00 PER MONTH SUBS
Osmetech's shares have dropped 0.375p today to 3.3p which looks like a good buying opportunity given the solid base provided by the existing Opti business. The potential of the new products and management's confidence about second half prospects.

However, the shares are very high risk and trade on a fairly wide spread.

The cash position is encouraging though and provides some security. The group finished the half year with 3.6 million after getting 1.5 million in cash from its all paper acquisition of Molecular Sensing after accounting for take over costs. Buy.

it would seem every 1 sees the price falling so follows the sheep and sells.
ER HELLO stop and think why you are selling !! what just because the share price is falling...................................TOP UP CANT YOU ALL SEE.

im following Kitcat not the sheep

mm are putting buys through as sells so the HEARD will get bigger

just sent JW an email wonder if i will get a reply?
and what he has to say!!!!

Depends on if you used a spell check. What did you ask?

You mean your not going to bar me from this site as well!

Change of heart, your out the sin bin!

So what were your questions to JW- When's the share price going to go up lots??

feb last year JW was available for comments on ADVFN said would be nice to be able to do the same and when he planned it as i felt that although im not bothered about the share price there were people who were loosing confidence in OMH and i felt it was his job to keep investors like our self's more updated and if people are able to put views and question accross it would shut some people up from moaning.
he simply replied............
No problem i will put he price up 3% today!!!! NOT im stil waiting for a reply what do you think or you going to slate me?

also pointed out its nice to see a director buying shares

Trouble is matey advfn doesn't do web casts anymore. I agree it would be a good opportunity to boost sentiment and tie up a few un answered questions amongst holders, its a shame they removed that service.

As far as directors buying shares i wouldnt hold your breath they are loaded up with options exercisable over 4p(ish without checking).

What would be nice is to see the 2 new key members of staff buying a small stake to show their confidence in the company & bringing OPTI-gene to the market. Perhaps this wont happen for sometime, until they have a better feel for how things are progressing......but i could be wrong!

No reply from the company yet Aztec0? Seems like your email went straight into the recycle bin..

DOING YOUR HOME WORK I SEE aztec0?
No reply yesterday so i sent it again stating that should a supplier MAIL an order worth a vast amount i should hope he replies a dam site faster than this!!!!!!
STILL WAITING.............MAYBE TRY THE OLD TELEPHONE

12,650,000 is that you MR WHITE in regards to my email!!!!! nice 2 see the MOTHS are flying!!!!

LOL

BANG JUST CALLED OMH
ALL IN A MEETING AND NOT TAKING CALLS 4:45PM THEY ARE CALLING ME BACK

IDEXX now showing VETSTAT on their website. Also being exhibited at a load of conferences and vet type gatherings around the US and UK over the next few months. (see competitors OMH thread for more details and dates etc)

http://www.idexx.com/AnimalHealth/analyzers/vetstat/index.cfm

Extracted from an alternative OMH thread, a recent conversation with DS.

snorky2 - 31 Mar'05 - 18:32 - 4107 of 4124 moderate post | add to banned list


HOPE THIS HELPS:

1. Will there be a trading statement at year-end?

NO we dont do a yearend trading statement but any info or news will be announced
through normal channels.


2. Is development still happening on OPTI IV for ROCHE? Or has the ROCHE OMNI filled that gap?

NO its on the back boiler since buying company but could be used in the future. If
they intend to use it Roch will have the first choice of refusal

3. Are the new OPTI product launches still on track? or has the development of OptiGENE taken precedence?

No. The Optigene has not taken precedence. It is 2 sets of people bringing 2 bits to the market and yes the OPTI products are on track


4. Is IDEXX progressing as well as anticipated?

Yes very happy. It was displayed at the trade show in January and the reaction was
very good way ahead of what they expected it to be and the response on what they
regard as firm leads with people leaving details saying yes they are very
interested and they are in the process of making and shipping the product around
the world.



5. Are IDEXX buying large chunk of machines or are they buying to order for their customers.

They buy in bulk in anticipation of getting buyers to buy from them so no cash flow problems. Because they buy more units they get them at a discount to the health care market and sell them on around the world. He stated that the discounts were agreed because of the amount of units that they were likely to be selling. It is the same product as used in the health care but different software. Different badge but basically the same product. IDEXX have the chance to sell significantly more products to one customer and quoted simple clean business. With IDEXX funding all the advertising and sales staff all omh do is manufacture and sell to them.



6. How are sales progressing across the company compared with quoted expectations in
the reports.
The fall in figures explained in reports: But the sales will still show a significant improvement in the second half.
Sales going well and if sales were not going as planned they would be obliged to inform the market. SO very good.



7. Are their any new uses that the optigene can be used for apart from what has already been mentioned in report?

Very simple and fast for DNA analysis, Test for absence of a certain gene, Diagnose a
Disease, Searching for a foreign DNA, Sexually transmitted diseases: chlymidia,



8. What will the OptiGENE be used for first.

Will be used for the principle use of virginal infections market and make this a
priority and one or 2 more areas to applying the optigene. If there are Thrombosis
markers for genetics and someone is about to go for an operation it is important in
knowing how that persons blood will clot and recovery process after surgery, there
are certain genes associated with thrombosis and it can help with the assessment of
how the patient can recover from that operation.


9. What needs to be done before a test for chlamydia can be
marketed and how soon do you think it will be on the market.

Working with lgc who have a very good chemistry is highly sensitive and works very well with the optigene. Using tests to identify the chlymidia bacteria works very well with the omh device. There were able to demonstrate in tests in London the instrument worked very quickly and accurate in identifying chlymidia. Will be showed in November which is Europes biggest medical show and they will be showing a finished product and with a view to shipping that product in the first half of next year. IT will not be used initially for sexually transmitted diseases that will be probably follow a few months after that. He stressed that it is very simple to use, accurate and very quick. Then went on to stress the importance of diagnosing patients quickly for obvious reasons.




10. When was the last time a MARKET analyst visited the company

One just started in America to follow the company.



11. I think I heard someplace that you did a presentation to some
institutes if how did it go.

Yes impressed and waiting for finished product on the market then they would show further interest in the company. Once the product sells and profits show they will show further interest but explained they dont mind buying at a higher price once the share price is moving. He said he believes they are on course but is yet still to come.


12. Which Company do you think will give omh the most competition and is omh doing to
combat this.

Optigene, there are lots of competition out there but this has the benefit of being very cost effective, the price of the unit and will sell cheaper in bulk buys, simple to use, quick. They are cheaper than all competitors and no one can offer the same benefits of the optigene. He goes onto say that people will move away from the labs to using the optigene.


13. Why do you think the share price is as low as it is and what in your opinion?
would be a fairer value up to date.
Even he has given up on trying to work out why its so low. They are working on building value to the company and at some point people will suddenly notice what omh is doing and that will be reflected in the share price in time. They are setting milestones and hitting them.



14. I think I heard someplace that omh had a meeting with some institutions to get
them interested in the company. If so how did it go and who were these companies.




15. Are there any plans to employ or reduce staff from within the company?

No plans to recruit or bin staff



16. Do you think this bird flue will benefit OMH in anyway on future sales and if so
how?

No, not unless there is a massive increase in infections. But some sales have been generated but are small.

23.Acqisistions.

They will be looking to buy into products from other companies that will fit in with omh and its products and will be make in their own factory in USA if opertunity arises.

Looks like Osmo are becoming the new distributor of a portable blood gas analysis device the AVOX 4000 replacing Abbott Labs.
http://www.osmetech.com/products/avox/avoximeter4000.htm A good way to build the portfolio with very little risk involved.
I wonder if this is a prelude to a buyout?
Guess this was the deal MW as chuntering about?

I think this could be replacing a deal they had with Abbot Labs to sell it.
Hmmmm now who do we know at Osmetech who has an Abbot connection....

http://www.avoxsystems.com/news.shtml
SAN ANTONIO, Texas, January 1, 2004 - Avox Systems Inc., announced today that it has terminated its sales promotion agreement with Abbott Laboratories. Under the agreement that ended on December 31, 2003, Abbott had sold Avox's unique portable co-oximeter, the AVOXimeter 4000, in the U.S. and Canada. In the U.S., Avox continues to sell the AVOXimeter 4000 factory direct. In addition, a private-label version of the AVOXimeter 4000, the GEMOPLTM*, continues to be available from Instrumentation Laboratory of Lexington, MA. The GEM OPLTM is currently sold worldwide. Avox Systems is now seeking foreign and domestic distributors to market the AVOXimeter 4000. Additional information is available at the company's website, http://www.avoxsystems.com.


Better get this thread updated!!!

Great News!

RNS Number:5558L
Osmetech PLC
27 April 2005





News Release



27th April 2005



Osmetech plc licences vial technology to Roche Diagnostics


Osmetech plc ("Osmetech") announced today that the AIM-listed international
diagnostics group has licensed its proprietary plastic tube technology to Roche
Diagnostics, Mannheim Germany. This plastic tube technology was acquired as part
of Osmetech's purchase of Molecular Sensing plc.

The worldwide non-exclusive license will enable Roche to develop, manufacture
and sell plastic consumable vials for use on its large installed base of
LightCycler(R) instruments as an alternative to existing glass vials.

The same technology has been incorporated into consumables to be supplied for
use with Osmetech's Opti GENE instrument scheduled to be exhibited at Medica
later this year. The Opti GENE is a fast and easy to use PCR based platform for
DNA and RNA analysis.

The terms of the license include an upfront payment to Osmetech plus royalties
based upon a percentage of the value of end user sales.

James White, CEO, Osmetech plc said, 'We are delighted that the acquisition of
Molecular Sensing has given us this opportunity to create additional revenue
before Opti GENE comes to market. Whilst those revenues will initially be
modest, we are pleased to be strengthening our relationship further with Roche
Diagnostics, one of the world's leading healthcare diagnostics companies.'



Ends



For further information:


James White, David Sandilands
Osmetech plc 020 7849 6027



Matthew Moth
madano partnership 020 7378 7033

Looking Good

RNS Number:9019L
Osmetech PLC
05 May 2005

5th May 2005

Osmetech plc

Trading Update

The Company stated in the interim results announcement in January 2005 that the
second half of the financial year ended April 2005 should see a significant
overall sales increase both from the level achieved in the first half of the
current year and that achieved in the corresponding period last year.

As expected, that improved performance has now been achieved with sales in the
second half in US dollar terms:

* up 44% against H1 this financial year
* up 32% against H2 last financial year

Excluding the one off benefits recorded last year of SARs related sales in Asia
and initial distributor pipeline filling, underlying OPTI sales are up by over
10% in the last 12 months.

Total sales for the full year of approximately $10,863,000 were 4% ahead of last
year, although there will be a 9%-10% negative currency translation impact
compared to the prior year due to the relative weakness of the US dollar when
these dollar based sales are converted into sterling.

As anticipated, Osmetech has begun to see strong volumes flowing through its
OEM
manufacturing and supply agreement with IDEXX Laboratories, Inc. to provide a
customised OPTI CCA analyser, 'VetStat',
for veterinary markets.

The VetStat electrolyte and blood gas analyser was first exhibited by IDEXX in
January this year and is in the process of being rolled out around the world.
Initial interest has been very encouraging and IDEXX has already taken delivery
of a greater number of units than expected. On April 29th, at an investor
update, IDEXX announced that it has signed a major five year contract to supply
Banfield, the US's largest private veterinary practice operating from more than
450 locations, with a range of products, including an order for 'VetStat'
instruments.

Good progress is also being made with IDEXX on the development and supply
contract to create a new platform for measuring critical care parameters based
on Osmetech's proprietary optical
fluorescence technology. Both IDEXX contracts
are for a period of at least 10 years.

The new German sales office, Osmetech GmbH,
commenced trading at the start of
April and is now the exclusive distributor for OPTI products in this important
market. It has achieved a good first month of consumable sales to customers
operating the existing installed base of instruments. This direct sales
operation should improve the Group's ability to grow more aggressively in the
largest European healthcare market when the new OPTI and Opti GENE products are
launched.

Since the acquisition of Molecular Sensing plc ('MS') in October 2004, the
development of the Opti GENE genetic testing platform has continued on
schedule.
Osmetech plans to show the Opti GENE
instrument for the first time at the AMP
(US) and Medica (Europe) trade exhibitions in November this year with sales
likely to commence in the first half of 2006.

Osmetech has also licensed its proprietary tube technology, used in the Opti
GENE device and acquired during the acquisition of MS, to Roche Diagnostics. The
worldwide non-exclusive license will enable Roche to develop, manufacture and
sell plastic consumable vials for use on its large installed base of
LightCycler(R) instruments as an alternative to existing glass vials.

James White, Chief Executive, Osmetech plc said,

'As anticipated, the second half of our financial year has been strong with OPTI
sales hitting our targets.

'Looking ahead we expect continued strong growth through the IDEXX trading
relationship and an increased contribution from new OPTI products.

'We are delighted with the progress we have made following the MS acquisition.
In addition to the licensing agreement that we have signed with Roche
Diagnostics our Opti GENE instrument and assay development programme is on
track
to deliver a strong point of entry into the fast-growing genetic testing market.

'As well as exploiting the opportunities that we have within our existing
portfolio of healthcare diagnostics products, we will also continue to search
for other opportunities to grow the business and leverage our operations further
through appropriate acquisitions.'

The full year preliminary results for the year ended 30 April 2005 are expected
to be announced in July 2005.

Ends

For further information:

James White, David Sandilands
Osmetech plc 0207 378 7033

Matthew Moth
madano partnership 0207 378 7033

There have been several significant developments since I started this thread.
Osmetech are now selling the AVOXIMETER 4000 worldwide (- USA) in a deal with AVOX.
Roche have licensed the plastic tubing technology Osmetech acquired as part of their purchase of Molecular Sensing Ltd.
UTI would appear to be more or less dead though the BV e-nose may have some life left in it yet.
The deal with Idexx to supply OPTI-CCA machines as VETSTAT is progressing better than expected with IDEXX have landed a contract to supply a leading American national vetinary hospital chain. 450 additional VETSTAT machines are required to fulfil this deal.
The company have issued a trading update announcing sales are up 4% on last year and that they have now opened a sales department in Germany.
GENEDRIVE has been re-branded as OPTi-GENE and is to be displayed both here and in America in November and then there is the yet to be formally announced OPTI -LION, a device to measure electrolyte and pH analytes.

Better get my finger out and get this thread updated.

Looks like something is happening at last with OMH.
MMs 6v2 and some chunky trades going through.
Wonder if some news has leaked?

pth

would appear so

Lots of activity in OMH this morning and over the last few days. All started by this news:

Osmetech to buy CMS from Motorola, to raise 11 mln stg via placing
AFX


LONDON (AFX) - Healthcare diagnostics company Osmetech PLC said it is buying Clinical Micro Sensors Inc (CMS) from Motorola Inc to strengthen its position in genetic diagnostics testing.

Payment will be in the form of 78 mln warrants which Motorola can subscribe to at 1.75 pence.

In addition, Osmetech is raising 11 mln stg via a placing of shares at 1.75 pence to fund the working capital requirements of the enlarged group.

Osmetech said Motorola will invest 3.7 mln stg in the placing.

'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and we believe that these products have significant market potential,' said James White, Osmetech CEO.

Price got hammered on release, but mutterings of a Bid in the Zoo, and significant activity today, maybe worth a punt, DYOR etc etc.

pth

Bid rumours being mentioned as well.

mjr

that's what I said in the last line of my post!!

Keep up! LoL

pth

pth - I had a small amount of these and as part of a "dog clearing" exercise (similar to your own) ditched them recently and bought more DGT.

OMH may come good in several years time, it's always been jam tomorrow with them - so be prepared for a long wait to get any decent return.

Having said that watch them double in price now over the next two weeks just after I've sold lol !

og

This is one of the dogs I decided to keep and give them a bit of a chance. Don't really have much invested in financial terms and have probably thrown a bit more good money after bad today as have averaged down. So the dog has grown another tail! Very speculative now, particularly as they are doubling the amount of shares in issue with the CMS acquisition. You never know, if a Bid does transpire I might escape break even!

pth

By the way, two of my cleared out stubborn dogs have now started to show signs of life again. Amazing, isn't it?

Tipped as a speculative buy today by UK-Analyst.

This should ensure a mark-up Monday morning and plenty of buyers. If there is any overhang, this should help to clear it.

The article basically says that, with major companies ie Motorola having a big interest in OMH now, things may start to turn around.
Also results may show a good revenue from their previous acquisition that they have been keeping quiet about?

Looking good.

Yip, looks strong. Rising on decent volume, those panicking & selling on the placing RNS can now buy back for a healthy premium LOL. Roll on December when OPTIgene gets released!

Osmetech - Speculative buy at 1.875p
Says Bill Johnston, editor of WatsHot.com
Someone wrote to me a while back with intriguing questions about Osmetech (OMH). Was there a stalker seeking to manipulate the share price? To capture that elusive electronic nose just as it sniffed into life? The shares then stood at 2.9p. What was being suggested to him and others was that some individual or group was seeking systematically to create a dispirited ambience so as to allow the assets to change hands, just before a turning in the long trail of losses brought sudden prosperity to the company. I thought that share-price manipulation tended to be cruder, more obvious and shorter-term.

Well, if there is a stalker, he is certainly playing the long game, for he never appeared, the shares are now 1.875p. But what is Osmetech? And where will the next move be?

Former Official List tech-flop Osmetech (the company used to be called AromaScan) moved markets in 2002 and whilst new to AIM, bore many characteristic marks of a certain type of company already quoted there - that of the expensive pursuit of ground-breaking technology in search of those sunlit uplands where the product is in widespread demand and the money starts to pour in. Needless to say all it had done so far was pour out, and been enabled to do so by 17 million pounds in new monies raised in the preceding four years alone. That sum was supplemented by another 5 million pounds raised at 2p per share, an operation which accompanied a move to the alternative market.

When micro-organisms metabolise they emit volatile components that often have a characteristic smell. Osmetech's research had been concentrated on the development of sensors to detect these smells. That four-year period too only referred to the period when the board decided to concentrate on the application of its gas-sensing technology on the area of healthcare, and mostly on highly specific targets at that, eventually deciding to focus upon the diagnosis of urinary tract infections and related conditions; to good effect indeed, as FDA approval had been received in respect of one medical screening device. The company pointed out that the medical disciplines of obstetrics and gynaecology, STD clinics and surgical wards, to say nothing of primary care physicians and general practitioners, comprised the vast market at which the instruments are aimed - worth $100 million in the United States alone.

In order to provide the additional resources to fuel the business towards that longed-for destination of positive cash flow, the burn rate was to be reduced to 200,000 pounds per month, and the usual ritual sacrifice was duly conducted as four directors trudged from the boardroom, leaving the Chief Executive of three years, a former advisor of venture capitalists, a bit more space. His first major move was acquisition of OPTI, a blood-gas analysis business based in the United States but owned by Roche Diagnostics. This was early in 2003, and cost $3.5 million - but Roche put $1 million back into Osmetech for 4.5% of the enlarged equity. OPTI, with a 4,000-strong installation base, was expected to generate $7 million of sales in the 12 months following completion. The assertion was that its cash-generative characteristics would give a two-year payback. Just the same, in October of the same year 2 million pounds more was raised at 3p per share. The following year, September 2004 an all-paper bid in ordinary shares - 3.1 million pounds - was tabled in respect of the acquisition of OFEX-quoted Molecular Sensing PLC. Molecular Sensing develops tools utilising polymerase chain reaction techniques which are expected to be complementary to the expertise of Osmetech.

Interim sales to October 2004 were 2.4 million pounds against the 3.4 million pounds recorded for the previous year, this being partly due to an extraordinary spike in the previous year due to SARS in China, and partly to the weak dollar. The acquisition of Molecular Sensing had seen the cash in the enlarged balance sheet buttressed by almost 2 million pounds, to 3.6 million pounds; whilst the period had produced a 1 million pounds operating loss; and although much stronger trading was expected in the second half, any question of profit was scrupulously avoided. A trading update in May of this year told of sales in that second half (to April) 44% ahead and was grimly positive - but no more.

Then last week came another deal as the company agreed to acquire a US organisation, CMS, from Motorola. CMS is a developer of instruments in the field of genetic diagnostics testing. CMS cost Motorola $280 million ten years ago, when the giant was interested in electrochemical detection. Under the agreement Osmetech has acquired CMS free of debt and free of cash, and Motorola will retain responsibility for and will indemnify Osmetech in respect of other liabilities prior to completion. The consideration is unusual - the issue to Motorola of 78 million warrants at 1.75p per share. Not only that, but Motorola will invest 3.7 million pounds at the same 1.75p, and this will play a key part in an issue of 629 million shares in total to raise 11 million pounds in order to consolidate the new deal, and carry it forward. The two CMS tests which are nearest to market are for Cystic Fibrosis and a family of enzymes CYP450 the mutation of which impact how well individuals metabolise drugs. The enlarged group believes that the new technology is complementary to that of OPTI and gives a strong foothold in the fast-expanding genetic diagnostics market

The habit of making losses and seeking some means of funding them is ingrained in many hi-tech companies, and it looked as though it would take a mighty effort or a major event to add much allure to this company - however clever the technology. If OPTI is gambolling to good effect as expected, the financial benefits have been well concealed. It doesn't look as though Motorola's sally into the market has done its shareholders much good. However, with a couple of powerful giants now having an interest in Osmetech it might - just might - start to change. A speculative buy for the brave.

can anyone help explain this statement as i am a little confused as what this means as never heard of sub-divided shares ?

The first resolution proposed at the EGM was to sub-divide each Existing Share
into 1 ordinary share of 0.01p each and one Deferred Share. Now that this
resolution has been passed, subject to the completion of the Placing Agreement,
it is expected that dealings in the Existing Shares will cease at 4.30 p.m.
today, 25 July 2005 and dealings in Sub-Divided Ordinary Shares will commence
tomorrow, 26 July 2005.

For Shareholders holding their Existing Shares in uncertificated form, the
relevant CREST accounts will be credited with the Sub-Divided Ordinary Shares
tomorrow, 26 July 2005, in place of their Existing Shares. For Shareholders
holding their Existing Shares in certificated form, new share certificates will
not be issued in respect of the Sub-Divided Ordinary Shares,

I think its something to do with a consolidation they are planning later this year.

Consolidation?

10 for 1. Looks like the MMs have used it as an opportunity to mark the SP down

Hell of a lot has been happening in the last few months its a bit of a job keeping on top of it all. To get an idea where we are at now here is a long in depth interview with James White by Ian Roberts, analyst for Wallstreet Reporter....VERY positive, upbeat and bullish...!!! Well worth listening to, and should surely bring more US interest!!

http://www.wallstreetreporter.com/profiles/Osmetechplc.html

Not forgetting this from the highly respected Investors Chronicle website, pinched from advfn, thanks DP. Surely Shares Mag will follow with a full on BUY tip this week or next.

4 November 2005
Sniffing out value

Once upon a time, Osmetech was best known for developing sensing technology that emulates the human nose. This is still a substantial part of its business, and the origin of its name (osme is Greek for smell). But a series of well-executed acquisitions over the past couple of years have turned it into a broader based diagnostics company. Todays trading update, which has sent the shares 20 per cent higher, shows some of the rewards of those deals.

Osmetech bought the OPTI range of blood gas analysers from Roche, the Swiss healthcare giant, for just $2.5m at the start of 2003. The devices are used in operating theatres and emergency rooms to give quick read-outs of critical gas and electrolyte levels in patients bloodstreams. Although formerly owned by a Swiss company, OPTI had a US-based sales force.

And look what theyve done: sales in the first six months were 3.74m, up 52 per cent on last year and considerably more than the price paid for the business. The growth came from a new version of an existing product, and strong sales of a related product used in the veterinary market.

The company says its not over yet, either: two new OPTI products are due to be launched shortly and management is talking about a very strong end to the year. Market expectations for OPTI sales are likely to be significantly exceeded in 2005 and 2006.

Osmetech has another division, Molecular Diagnostics, where acquisitions have also played a part. It bought Clinical Micro Sensors (CMS) from Motorola for around 3.7m, a deal which gave it access to more complex genetic diagnostic technology. The first products from this division are due on market in the first half of 2006.

Its noticeable that both Roche and Motorola were happy to be paid partly in Osmetech shares. Roche ended up with $1m worth of them, and Motorola invested 3.7m and has warrants over more. The shares were issued at a penny each to Roche and 1.75p apiece to Motorola. The company has since had a 10-into-1 share consolidation, so at 17.5p (latest share price here) the shares are effectively unchanged since the CMS deal. House broker Evolution Securities was forecasting 2006 sales of 8.63m, giving a loss of 7.74m (check forecasts here) but those numbers are now likely to be upgraded. The shares look good value

First look at the new OPTI-GENE as released at recent Medica and AMP medical trade shows.

http://www.chelsea.co.uk/images/Osmetech%20Homeland.pdf

Told you all it was about to come good

Further confirmation from an insider news letter that FDA approval is close than ever.

http://www.bioarraynews.com/

Osmetech's eSensor Nears FDA Clearance as Qiagen OKs Bundling Deal
For Osmetech, the deal shows that its molecular diagnostics platform is closer to winning clearance from the FDA because Qiagen's kits must formally be made a part of the platform before it can be sold to labs.
31089

New update with major shareholder list.131

The Osmetech website has been update. All mention of the enose has been removed. Guess its finally dead then!

http://www.osmetech.com

The company also has a bust year ahead of it. Osmetech products are being launched / displayed at 12 exhibitions next year.

http://www.osmetech.com/exhibits.htm

Found this interesting little PDF about the OPTI-CCA.
It gives some more close up detail and information on how it works and a list of the some of the organisations in the UK using it.
Interstingly BUPA have 17 of them, perhaps there is great potential here for pushing the rest of Osmo product line.


http://www.bio-stat.com/files/downloads/26.pdf

Interestingly Gordon Hall was previously a director of Biostat and nodoubt will maintain connections with them.

Osmetech GMBH are starting to get a little more exposure as well.
http://www.notfalllabor.de/Osmetech-GmbH/40-0-0-0-94-0-0-O.html

Nice rise today have I missed some news?

No not yet but if you don't get in quick you could well do.
Osmetech have moved their year end to 31/12 so a trading statement is expected real soon.
Also news from the FDA re the Cystic Fibrosis test is due at any time.
So still time to grab a piece of the action before then. Still you could always hold on to them as the company are launching a number of products this both independantly and with partner in vetinary diagnostics Idexx.

Results Out On Tuesday

Investors Chronicle says Good Value BUY

eSensor gets a new set of clothes. How sexy is that. Wouldnt look out of place on the starship enterprise.
Bewarned these images are massive and will give your internet connection a kicking.
I said in an earlier posting that I thought esensor might be delayed. Well I take that back. This is the make over I was expecting to see before launch. These are publicity shots from 8 days ago. Get them while there hot!

http://tech-dimensions.com/osmetech/Pics/Image_0224.JPG

New consumables for eSensor.
http://tech-dimensions.com/osmetech/Pics/Image_0245.JPG

Rest of the pics here.

http://tech-dimensions.com/osmetech/Pics/



Osmetech GMBH are now selling the AVOX4000 in addition to the other Osmo products. This core division in the Osmetech

sales push is starting to grow very nicely.
http://www.notfalllabor.de/Osmetech-GmbH/40-0-0-0-94-0-0-O.html

Osmetech GMBH are also exhibiting at the
47. KONGRESS DER DEUTSCHEN GESELLSCHAFT F PNEUMOLOGIE .
This meeting is not listed on Osmo website.
http://www.dgp2006.de/index.php?Auswahl=Industrie&Menue=Ebene0

Want to know how much OPTI bits cost? Well looky here.
http://www.surrey.ac.uk/MHRA/Pages/GuildfordEvaluations/CurrentReports/BloodGas/Blood%20gas%20pdfs/Osmetech%20OPTI%20CCA.pdf

Think you're clever? Have a go at debugging some of the code that drives opti.
http://nickhennenfent.com/gasgauge.c.htm

I think there can be little doubt now that Osmo are going to push their DNa technology in to the Vetinary market.
Yet another senior scientist is being recruited for this role.
http://www.socalbio.org/career_center/open-position/OMDJD_Sr[1]._Scientist.doc


This one is interesting. It makes reference to "management of an outside contractor developing a large software project." I wonder what that large software project could be.

http://www.socalbio.org/career_center/open-position/OMDJD_Sr[1]._Software_Eng.DOC


News link to Southern California Biomedical Council. eSensor to start full scale manufacturing in the spring. From the pics above looks like it already has!

http://www.socalbio.org/newsletter/spring2006/Synergies_Spring_2006.pdf


Looks like the recent Arab Health event sporned a new buisness relationship.
http://www.arabhealthonline.com/index.cfm?page=exhibitor_details&menuid=&RecordNo=1&id=4659&type=alphabet&c=O&option=&keyword=&style=1

http://www.transemirate.com/osmetech.htm

Presumably the opTIT device mentioned on the site a special version modifed for those of a poisson persuasion.

And the caribbean.
http://www.andarint.com/manufacturer_osmetech.php
And Norway.
http://www.mednett.no/english/blodgass_uk.html

update with gartmore holding

Investors Chronicle says Good Value BUY

Updated with the most recent shareholder infiormation.

1,300,00 BUY just before close = c300,000 investment!

OMH (Osmetech) Tipped as a BUY in todays Sunday Telegraph
Sunday Telegraph (UK) - Apr. 23, 2006

KEEP an eye on Osmetech, the healthcare diagnostics group (24p).

Under the stewardship of James White, the company has developed into a business with sales, mainly thanks to a handful of acquisitions.

In results published last month, Osmetech revealed that sales for the eight months to December 31 were up by 78 per cent on the corresponding period.

Its investment in its critical care business is also paying off, with sales up by 64 per cent to $14.8m ( pounds 8.3m).

Since then it has announced the launch of its eSensor cystic fibrosis carrier detection (CFCD) test and its eSensor 4800 DNA detection instrument.

The eSensor system can be used to perform molecular tests that require the simultaneous analysis of multiple genetic information. Product shipments are expected to begin on schedule during the first half of this year, the company said.

We believe the shares look like good value. Buy.

The fuse has been lit...

Updated with new shareholder data.